• Home
  • Contact Us
  • Try it!
  • Blog
  • Vizit Graphs

Follow us

Recent Posts

  • Biovista Harnesses New Kinds of Augmented and Artificial Intelligence to Address COVID-19 August 25, 2020
  • Repositioning Safety May 22, 2020
  • Artificial Intelligence firm Biovista repositions four promising therapeutics against COVID-19 April 22, 2020
  • Business Development Agent in Japan February 12, 2020
  • High Throughput Layout and Copy Paste July 5, 2019

Biovista Vizit

Biovista Vizit

  • Try it!
  • Blog
  • Vizit Graphs

Mechanistic analysis of Tocilizumab

June 19, 2020COVID-19, Vizit Graphs
Mechanistic analysis of TocilizumabEftychia Lekka2020-08-18T07:45:39+00:00
Mechanistic analysis of Tocilizumab

Tocilizumab (Acterma) is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients.

Explore the live graph.

Tags: ACE, ACE2, ALBUMIN, ANGIOTENSIN II, APOE, BLOOD VESSEL DISEASE, COVID-19, FIBRINOGEN, HEMOGLOBIN, ICAM1, IL1B, IL6, LACTATE DEHYDROGENASE, NFKB1, RAS, SARS-COV-2, THROMBIN, TNF, VEGFA

Post navigation

← Mechanistic analysis of combination IFB-a2b chlorpheniramine, ibuprofen
Mechanistic analysis of Azithromycin →

Vizit Graphs Tag Cloud

SARS-COV-2 ALBUMIN METFORMIN APOPTOTIC PROCESS IMMUNE RESPONSE NEUTROPHILS COAGULATION CD4 INFLAMMATORY RESPONSE RHEUMATOID ARTHRITIS PD-1 TNF IMMUNITY AGING IL10 TMPRSS2 ANGIOTENSIN II CELL DIFFERENTIATION LISTERIA MONOCYTOGENES ACE2 AUTOPHAGY IL2 CANDIDA ALBICANS CELL PROLIFERATION RAS CASP3 ESCHERICHIA COLI CANCER IL6 INFLAMMATION IL1B LACTATE DEHYDROGENASE NFKB1 INSULIN ALZHEIMER'S DISEASE MYALGIA IFNG COVID-19 INTERFERON HELICOBACTER PYLORI PSEUDOMONAS AERUGINOSA COGNITION PARKINSON DISEASE STAPHYLOCOCCUS AUREUS ACE

© 2021 Biovista Vizit All Rights Reserved.